David Caudell to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications David Caudell has written about Xenograft Model Antitumor Assays.
Connection Strength
0.067
-
Jimenez H, Wang M, Zimmerman JW, Pennison MJ, Sharma S, Surratt T, Xu ZX, Brezovich I, Absher D, Myers RM, DeYoung B, Caudell DL, Chen D, Lo HW, Lin HK, Godwin DW, Olivier M, Ghanekar A, Chen K, Miller LD, Gong Y, Capstick M, D'Agostino RB, Munden R, Merle P, Barbault A, Blackstock AW, Bonkovsky HL, Yang GY, Jin G, Liu L, Zhang W, Watabe K, Blackman CF, Pasche BC. Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2?T-type voltage-gated calcium channels and Ca2+ influx. EBioMedicine. 2019 Jun; 44:209-224.
Score: 0.042
-
Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Blood. 2012 Apr 12; 119(15):3561-70.
Score: 0.025